Somatostatin for injection

1. It can inhibit the secretion of growth hormone, thyroid stimulating hormone, insulin, and glucagon; 2. It can inhibit the secretion of gastric acid stimulated by the test meal and pentagastrin, and inhibit the release of pepsin and gastrin; 3. It can significantly reduce visceral blood flow, reduce portal vein pressure, reduce collateral circulation blood flow and pressure, and reduce liver blood flow; 4. It can reduce the endocrine secretion of the pancreas, the secretion of the stomach, small intestine, and gallbladder, reduce enzyme activity, and have a protective effect on pancreatic cells; 5. It can inhibit the secretion of glucagon; 6. It can affect gastrointestinal absorption and nutritional function.

Somatostatin acetate

This product is white freeze-dried powder

Severe acute esophageal varicose bleeding. Severe acute gastric or duodenal ulcer bleeding, or complicated by acute erosive gastritis or hemorrhagic gastritis. Adjuvant treatment of pancreatic, biliary and intestinal fistulas. Prevention and treatment of complications after pancreatic surgery. Adjuvant treatment of diabetic ketoacidosis.

The lyophilized powder of the drug must be dissolved in saline before use. Staminin is administered intravenously by slow bolus injection (3 to 5 minutes) of 250 micrograms or by continuous drip at a rate of 250 micrograms per hour (equivalent to approximately 3.5 micrograms per kilogram of body weight per hour). For continuous drip administration, a 3 mg vial of staminin is used to prepare a 12-hour solution. The solvent can be either saline or 5% glucose solution. The infusion volume should be adjusted to 250 micrograms per hour, and the use of an infusion syringe is recommended. For the treatment of severe acute upper gastrointestinal bleeding (including esophageal variceal bleeding): It is recommended to first slowly inject 250 micrograms of staminin intravenously as a loading dose, followed immediately by intravenous drip administration of 250 micrograms per hour. When the interval between two infusions is greater than 3 to 5 minutes, 250 micrograms of staminin should be injected intravenously again to ensure the continuity of administration. When the heavy bleeding is stopped (usually within 12 to 24 hours), treatment should be continued for 48 to 72 hours to prevent recurrence of bleeding. For the above cases, the usual treatment time is 120 hours. For adjuvant treatment of pancreatic fistula, biliary fistula, and intestinal fistula: Continuous intravenous drip at a rate of 250 micrograms per hour should be used until the fistula is closed (2 to 20 days). This treatment can be used as an adjunct to total parenteral nutrition. After the fistula is closed, intravenous drip of silamin should be continued for 1 to 3 days, and then gradually discontinued to prevent rebound effect. Prevention and treatment of complications after pancreatic surgery: At the beginning of the operation, as an adjuvant treatment, silamin is dripped at a rate of 250 micrograms per hour; after the operation, the drip is continued for 5 days. Adjuvant treatment of diabetic ketoacidosis: For patients with ketoacidosis, intravenous drip of silamin at a rate of 100 to 500 micrograms per hour combined with insulin treatment can relieve ketoacidosis within 3 hours and restore blood sugar to normal within 4 hours.

A few cases experienced nausea, dizziness, blushing, etc. When the infusion rate of silamin was higher than 50 micrograms per minute, the patient would experience nausea and vomiting.

Patients with confirmed allergies to silafenamide should not use this drug. Pregnant women should avoid using this product unless there is no other safe alternative.

Precautions during pregnancy and lactation: Avoid using this product by pregnant women unless there are no other safe alternatives.

Since silatin inhibits the secretion of insulin and glucagon, it will cause a short-term drop in blood sugar level in the early stage of treatment. It should be noted that patients with insulin-dependent diabetes should test blood sugar concentration every 3 to 4 hours after using this product. At the same time, during the administration of glucose required by insulin, it should be avoided. If it must be given, insulin should be used at the same time.

This product should be stored in a dark and dry place below 25°C.

0.25mg

Qingdao Guoda Biopharmaceutical Co., Ltd.

• Founded in:

  1999-01-20

• Address:

  Qianwangang Road, Qingdao Economic and Technological Development Zone

• Tax NO.:

  91370200713716738U

• Registered Funds:

  107.9964 million yuan

• Website:

  Log in to view

• Email:

  Log in to view